Catalog No.
Product Name
Application
Product Information
Citations
-
NF-κB p65 Inhibitor, Apoptosis Inducer
N-Desmethyldauricine is an inhibitor of NF-κB p65 with significant apoptotic effects. It effectively reduces p65 protein expression, induces apoptosis, and arrests the cell cycle at the G0/G1 phase. Additionally, N-Desmethyldauricine attenuates intercellular adhesion and inhibits the growth of 3D spheroids derived from triple-negative breast cancer. This compound is useful for research involving triple-negative breast cancer dynamics and therapeutic strategies. -
Anti-leukemic Compound
(E/Z)-Sinigrin free base is an orally active aliphatic thioglucoside exhibiting anti-leukemic properties. It is hydrolyzed by myrosinase to produce allyl isothiocyanate, which demonstrates an IC50 of 2.71 μM against HL60 leukemia cells. The hydrolysis products also activate apoptosis pathways, inhibit NF-κB and MAPK signaling, and stimulate phase II metabolic enzyme activity, showing potential in cancer therapy, anti-inflammatory research, and infectious disease studies. This compound can be naturally sourced from Brassica nigra, Brassica juncea, and other Brassicaceae plants. -
Anti-inflammatory Agent/Anticancer Agent
Cryptolepine is a multi-potent alkaloid that serves as an anti-inflammatory and anticancer agent. It functions primarily as an inhibitor of c-Myc, mTOR, NF-κB, HIF-1, and MAPK while activating AMPKα1/2, leading to various biological effects including DNA intercalation and inhibition of topoisomerase II. These activities result in disrupted mitochondrial dynamics and induction of apoptosis in cancer cells. Cryptolepine shows promise in research applications focusing on tumors such as melanoma and hepatocellular carcinoma, as well as in studies related to malaria, inflammatory diseases, and diabetes. -
Apoptosis Inducer
Sanguinarine (gluconate) is a benzophenanthridine alkaloid that functions as an apoptosis inducer. It promotes apoptosis through the generation of reactive oxygen species (ROS) and is linked to the activation of key signaling pathways, including JNK and NF-κB. This compound is utilized in research exploring mechanisms of apoptosis and oxidative stress responses in various cell types. -
Superoxide Radical Scavenger
Opc 14117 is an orally active superoxide radical scavenger that effectively crosses the blood-brain barrier. It inhibits oxidative stress cascades, leading to a significant reduction in tissue osmotic pressure and alleviation of brain edema in contusion models. Additionally, Opc 14117 blocks the NF-κB-dependent apoptotic pathway in striatal neurons exposed to Quinolinic acid, reducing necrotic volume, protecting hippocampal CA3 neurons, and restoring cognitive function. This compound is useful for studying secondary brain injury and enhancing neurological prognosis. -
NF-κB Inhibitor
15-Deoxy-Δ12,14-prostaglandin A1 is a potent inhibitor of NF-κB signaling, functioning through the modulation of inflammatory pathways. It has been shown to induce apoptosis and effectively inhibit TNF-α-induced upregulation of adhesion molecules on endothelial cells, thereby preventing monocyte arrest. This compound is valuable for research in inflammation, cardiovascular diseases, and apoptosis studies. -
NF-κB Inhibitor
Declopramide is a potent NF-κB inhibitor that exerts antitumor effects by inducing apoptosis in cancer cells. It has demonstrated efficacy in inhibiting the proliferation of HL60 and K562 cell lines, as well as reducing tumor growth in a mouse model of human brain astrocytoma (T24). Additionally, Declopramide functions as a chemosensitizer, making it a valuable tool for investigating therapeutic strategies in cancer research. -
Anti-Inflammatory Agent
2,4′-Dihydroxybenzophenone acts as an anti-inflammatory agent by targeting the hydrophobic pocket of MD2, effectively inhibiting the dimerization of TLR4. This compound demonstrates significant biological activity by suppressing LPS-induced mitochondrial reactive oxygen species (mtROS) production and attenuating the inflammatory response through downregulation of pro-inflammatory mediators, including MyD88, p-IRAK4, and NF-κB. Additionally, 2,4′-Dihydroxybenzophenone serves as an effective UV absorber, enhancing its utility in research on oxidative stress and inflammation. -
μ Opioid Receptor Antagonist
β-Funaltrexamine hydrochloride is a selective and irreversible antagonist of the μ opioid receptor. This compound demonstrates significant anti-inflammatory and neuroprotective properties by reducing TLR4 signaling, inhibiting cytokine-induced iNOS activation and neuroinflammation, and mitigating neuronal degeneration. Additionally, β-funaltrexamine hydrochloride inhibits NF-κB signaling and chemokine expression in human astrocytes and murine models. It is a valuable tool for research related to neurodegenerative diseases, including stroke. -
Methoxyflavone
6-Methoxyflavone is a methoxyflavone compound that primarily targets neuroinflammation pathways. It effectively suppresses neuroinflammation in microglia by inhibiting the TLR4/MyD88/p38 MAPK/NF-κB signaling cascade and activating HO-1/NQO-1 pathways. Additionally, 6-Methoxyflavone induces S-phase cell cycle arrest through the CCNA2/CDK2/p21CIP1 mechanism in HeLa cells. Its diverse biological activities make it valuable for research focused on cancer, inflammation, and neurological disorders. -
TLR4/NF-κB Inhibitor
TLR4/NF-κB-IN-1 is a selective inhibitor of the TLR4/NF-κB signaling pathway, demonstrating significant anti-inflammatory properties. This compound exhibits the ability to penetrate the blood-brain barrier, making it suitable for studies involving neuroinflammation. In murine models, TLR4/NF-κB-IN-1 effectively reduces acute neuroinflammation induced by lipopolysaccharides (LPS) while downregulating the expression of TLR4, phosphorylated NF-κB, and phosphorylated IκB-α proteins, providing a valuable tool for researching neuroinflammatory processes and their therapeutic modulation. -
TLR8 Antagonist
TLR8 antagonist-1 is a selective antagonist targeting Toll-like receptor 8 (TLR8). It effectively inhibits TLR8-mediated inflammatory responses and associated signaling pathways, including the recruitment of MyD88 and the activation of NF-κB and IRF pathways. This compound demonstrates significant anti-inflammatory activity, making it a valuable tool for research in inflammation and immune response modulation. -
TLR2 Agonist
Pam2Cys is a TLR2 agonist that acts as an immunostimulant by binding to TLR2, activating dendritic cells, and initiating the TLR2-dependent NF-κB signaling pathway. This compound promotes dendritic cell maturation through the upregulation of MHC II molecules, enhances innate immune signaling, and drives pro-inflammatory responses, including the release of IL-12 and other cytokines. Additionally, Pam2Cys serves as a lipid moiety in synthetic lipopeptide vaccines, boosting immunogenicity, while selectively inducing pro-inflammatory macrophage activation. Research applications include studies on tuberculosis and influenza A virus infections, as it effectively recruits immune cells and mitigates infection-related symptoms without compromising adaptive immunity. -
TLR4/MyD88/NF-κB Inhibitor
SjDX5-271 is a small peptide inhibitor targeting the TLR4/MyD88/NF-κB signaling pathway. It is known to induce cell polarization and mitigate hepatic inflammation, demonstrating protective effects against liver ischemia-reperfusion injury in mouse models. This compound is valuable for research in immunology and liver-related inflammation studies. -
Anti-Inflammatory Agent
4-Methoxylonchocarpin is an orally active anti-inflammatory agent that primarily targets Toll-like Receptor 4 (TLR4). This compound effectively inhibits the binding of lipopolysaccharides (LPS) to TLR4, leading to the suppression of NF-κB activation and the downregulation of pro-inflammatory cytokines such as TNF and IL-6. Additionally, 4-Methoxylonchocarpin reduces the phosphorylation of TGF-beta activated kinase 1 and mitigates the expression of IL-1β, IL-17A, and TNF in a 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis mouse model, demonstrating its potential in anti-inflammatory research applications. -
Anti-inflammatory Agent
Chlojaponilactone B is a lindenane-type sesquiterpenoid known for its anti-inflammatory properties. This compound functions by inhibiting Toll-like receptor 4 (TLR4), leading to a decrease in reactive oxygen species (ROS) production and downregulation of the NF-κB pathway. Consequently, it reduces the expression of pro-inflammatory cytokines, including iNOS, nitric oxide (NO), COX-2, IL-6, and TNF-α. Chlojaponilactone B is a valuable tool for research into inflammation and related pathways. -
TLR7/TLR9 Inhibitor
ODN 24888 is a guanine-modified inhibitory oligonucleotide (INH-ODN) that specifically targets TLR7 and TLR9 signaling pathways. It effectively inhibits interferon-alpha (IFN-α) secretion and NF-κB activation, while also reducing interleukin-6 (IL-6) release. ODN 24888 is valuable for studying immune and inflammatory responses and can be utilized as a vaccine adjuvant in various research applications. -
TLR Inhibitor
TIC10g is a dual inhibitor of toll-like receptors 7 and 9 (TLR7 and TLR9). It effectively decreases TNF-α release in mouse macrophages and human B lymphocytes, with IC50 values of 14.5 μM and 6.5 μM for TLR7, and 7.69 μM and 11.5 μM for TLR9, respectively. TIC10g also inhibits the activation of NF-κB and MAPK pathways, demonstrating potential as an anti-inflammatory agent in conditions such as systemic lupus erythematosus and rheumatoid arthritis. -
TLR4 Signaling Inhibitor
NCI126224 is a TLR4 signaling inhibitor that modulates immune responses by suppressing lipopolysaccharide (LPS)-induced production of key inflammatory mediators, including NF-κB, TNF-α, IL-1β, and nitric oxide. This compound demonstrates biological activity in the low nanomolar to low micromolar range, making it a valuable tool for research into inflammatory diseases and their mechanisms. Its ability to interfere with TLR4 signaling pathways positions NCI126224 as a significant reagent for exploring potential therapeutic strategies in inflammation-related studies. -
TLR4/NF-kB/MAPK Inhibitor
TLR4/NF-κB/MAPK-IN-1 is an inhibitor targeting the TLR4/NF-κB/MAPK signaling pathways. It exhibits significant anti-neuroinflammatory activity by suppressing the activation of these pathways, leading to reduced inflammatory responses. This compound is particularly useful for research applications focusing on neuroinflammation and related neurodegenerative diseases. -
TLR4/NF-κB Inhibitor
Ligusticum cycloprolactam is a potent TLR4/NF-κB inhibitor with significant anti-inflammatory properties. It has been shown to alleviate renal injury by effectively disrupting the TLR4/NF-κB signaling pathway in both in vivo and in vitro models. In studies, Ligusticum cycloprolactam reduces serum uric acid levels, diminishes tubular damage, and decreases inflammatory infiltration and interstitial collagen deposition, leading to improved renal function. This compound serves as a valuable reagent for research into hyperuricemic nephropathy. -
TLR1/2 Agonist
SMU-C409 is a Toll-like receptor 1/2 (TLR1/2) agonist, exhibiting an EC50 of 65 nM in HEK-Blue hTLR2 cells. It activates the TLR1/2–MyD88–NF-κB signaling pathway, leading to increased secretion of pro-inflammatory cytokines TNF-α and IL-1β, which promotes robust immune cell activation. With low toxicity observed in vitro, SMU-C409 serves as a valuable tool for cancer immunotherapy research. -
TLR1/2 Heterodimer Agonist
SMU-C68 is a selective small-molecule agonist of the TLR1/2 heterodimer, with an EC50 value of 0.009 μM. It effectively activates the NF-κB and MAPK signaling pathways, leading to the release of pro-inflammatory cytokines such as TNF-α and IL-1β. This compound is a valuable tool for investigating mechanisms of inflammation and cancer biology in research applications. -
NF-κB Inhibitor
NF-κB-IN-14 is an NF-κB inhibitor that effectively modulates inflammatory responses by significantly inhibiting nitric oxide production in LPS-stimulated macrophages, with an IC50 of 6.4 μM. This compound disrupts the TLR4-MyD88 protein interaction, leading to the suppression of the NF-κB signaling pathway. Additionally, NF-κB-IN-14 has demonstrated efficacy in reducing ear edema and inflammation in a mouse model of atopic dermatitis, highlighting its potential utility in inflammatory research. -
Toll-like Receptor (TLR) Ligand
Ste2Cys is a diacylglycerol cysteine-type lipid molecule that serves as a ligand for Toll-like Receptor 2 (TLR2). It activates the NF-κB signaling pathway, leading to the upregulation of MHC II class molecules on the surface of mouse bone marrow-derived dendritic cells. This compound is valuable for research into the development of immunologic vaccines and enhancing immune responses. -
TLR2 Agonist
TLR2 Agonist 1 is a highly potent agonist for human toll-like receptor 2 (TLR2), exhibiting an EC50 of 116 pM. It activates NF-κB promoter activity through TLR2/TLR1 heterodimerization, making it a valuable tool for studying TLR-mediated immune responses. This compound is applicable in research focused on inflammation, innate immunity, and potential therapeutic strategies involving TLR pathways. -
MyD88 Inhibitor
LM9 is a selective inhibitor of MyD88, a key adaptor protein in the Toll-like receptor (TLR) signaling pathway. By blocking the binding of TLR4 to MyD88, LM9 disrupts MyD88 homodimer formation and subsequent activation of the NF-κB signaling pathway. This compound demonstrates significant anti-inflammatory effects, mitigating atherosclerosis and fibrosis in models of obesity-induced cardiomyopathy. LM9 is valuable for research focused on understanding the mechanisms of inflammation, fibrosis, and cardiovascular diseases. -
μ Opioid Receptor Antagonist
β-Funaltrexamine (β-FNA) is an irreversible and selective antagonist of the μ-opioid receptor. This compound demonstrates significant anti-inflammatory and neuroprotective properties by modulating TLR4 signaling, inhibiting cytokine-induced iNOS activation, and reducing neuroinflammation. Additionally, β-FNA influences NF-κB signaling and chemokine expression in human astrocytes and murine models. It is an important tool for research into neurodegenerative diseases, including stroke. -
Steroidal Alkaloid Glycoside
Esculeoside A is a spirosolane-type steroidal alkaloid glycoside that primarily targets NF-κB and Nrf2/Keap1 signaling pathways. This compound exhibits significant cardioprotective and hypoglycemic properties, regulating glucose metabolism and modulating lipid profiles. Research applications include the study of diabetic cardiomyopathy, type 2 diabetes, atopic dermatitis, tumors, and atherosclerotic diseases. Additionally, Esculeoside A inhibits dendritic cell maturation and T-cell proliferation, and exhibits anti-tumor activity against breast cancer and melanoma cells. -
TLR4/JNK/NF-κB Inhibitor
TLR4-IN-2 is an inhibitor targeting TLR4, JNK, and NF-κB pathways. It demonstrates anti-inflammatory properties by reducing nitric oxide production in LPS-stimulated RAW264.7 cells, with an IC50 of 23.2 µM. By inhibiting TLR4 expression and diminishing JNK phosphorylation, TLR4-IN-2 effectively suppresses NF-κB activation and the transcription of inflammation-related genes, leading to lower levels of iNOS, COX-2, and various inflammatory mediators. This compound shows potential for investigating therapeutic strategies in inflammatory diseases such as rheumatoid arthritis and other inflammatory disorders. -
NF-κB Inhibitor
Ergolide is a selective NF-κB/p65 and NLRP3 inhibitor that effectively disrupts the NF-κB signaling pathway and inhibits the nuclear translocation of p65. By irreversibly binding to the NACHT domain of NLRP3, Ergolie suppresses inflammasome assembly, significantly reducing the production of inflammatory mediators such as NO and PGE2. This compound promotes apoptosis in cancer cells, induces autophagy, and generates reactive oxygen species (ROS). Ergolide also enhances the therapeutic efficacy of vincristine and has been shown to alleviate acute lung injury in models of sepsis and inflammation, contributing to research in metastatic uveal melanoma, neurodegenerative diseases, and acute lymphoblastic leukemia. -
BChE Inhibitor
Pteryxin is a potent butyrylcholinesterase (BChE) inhibitor (IC50 = 12.96 μg/mL) with additional multi-target mechanisms including inhibition of NF-κB, MAPK, NLRP3 inflammasome activation, and modulation of the Nrf2/ARE pathways. This compound demonstrates significant anti-inflammatory, antioxidant, and osteoclastogenesis inhibitory activities. Pteryxin is suitable for research applications related to inflammatory diseases, osteoporosis, diabetes, and neurodegenerative disorders such as Alzheimer's disease. -
PC Inhibitor
Anemoside A3-methyl 6-aminohexanoate is a potent pyruvate carboxylase (PC) inhibitor, exhibiting a Kd value of 10.1 μM against human PC. This compound influences cellular pathways through the PC/NF-κB/NLRP3 inflammasome axis, demonstrating significant efficacy in alleviating symptoms of DSS-induced colitis in murine models. Anemoside A3-methyl 6-aminohexanoate serves as a useful tool in colitis-related research and studies focusing on the modulation of inflammatory pathways. -
NLRP3 Inhibitor
Yadanzigan is a potent NLRP3 inhibitor that exerts its anti-inflammatory effects by inhibiting the NF-κB signaling pathway and reducing Reactive Oxygen Species production. This compound has been shown to mitigate LPS-induced acute lung injury (ALI) in murine models, highlighting its potential for research in inflammation-related conditions. Its mechanism of action positions Yadanzigan as a valuable tool for studying NLRP3-related pathways and their roles in various pathological processes. -
NOD1 Agonist
iE-DAP is a potent NOD1 agonist that activates the NOD1 receptor, leading to the stimulation of the NF-κB and MLCK signaling pathways. This results in enhanced cellular inflammatory responses and disruption of tight junction integrity, as evidenced by the downregulation of ZO-1 and Occludin gene expression. In term human trophoblast cell cultures, iE-DAP promotes the secretion of pro-inflammatory cytokines such as IL-6, GRO-α, MCP-1, IL-8, and MIP-1β. It is particularly relevant for research focused on mastitis and preterm birth, as it has been shown to induce fetal inflammation and impact fetal body weight in pregnant murine models. -
Sodium Channel Inhibitor
Articaine is a selective inhibitor of voltage-gated sodium channels, including rNav1.4, hNav1.7, and rNav1.8, demonstrating an IC50 of 15.8 μM for open-state Na+ channels. It effectively blocks Na+ influx, leading to local anesthetic effects and interruption of nerve impulse conduction. Additionally, Articaine exhibits anti-inflammatory properties by inhibiting NF-κB activation and the NLRP3 inflammasome pathway. This compound is valuable for research in dental anesthesia and inflammatory-related conditions, such as acute kidney injury. -
NLRP3 Inhibitor
NLRP3-IN-69 is a selective inhibitor of the NLRP3 inflammasome, targeting the activation of NF-κB p65. This compound effectively reduces LPS-induced overexpression of pro-inflammatory cytokines including IL-1β, as well as iNOS and COX-2, while inhibiting nitric oxide generation with an IC50 of 5.66 μM. NLRP3-IN-69 serves as a valuable tool in research focused on inflammatory diseases and the modulation of the immune response. -
COX-2/NLRP3 Inhibitor
COX-2/NLRP3-IN-1 is a selective inhibitor targeting both COX-2 and the NLRP3 inflammasome, with an IC50 of 1.53 μM for COX-2. This compound exhibits notable anti-inflammatory properties by disrupting the NF-κB/NLRP3 signaling pathway, making it a valuable tool for research into inflammatory diseases. It is suitable for studying the roles of COX-2 and NLRP3 in various biological processes and therapeutic interventions. -
NOD1/NOD2 Antagonist
NOD1/2 antagonist-2 is a dual antagonist of NOD1 and NOD2, exhibiting IC50 values of 2.36 μM and 4.16 μM, respectively. This compound effectively inhibits NF-κB and MAPK inflammatory signaling pathways, enhancing the efficacy of Paclitaxel in suppressing the growth of Lewis lung carcinoma. It is a valuable tool for investigating the roles of NOD1 and NOD2 in inflammation and cancer research. -
NF-κB Inhibitor
1-Caffeoylquinic acid is a potent inhibitor of NF-κB, demonstrating a significant binding affinity to the RH domain of p105 with a Ki value of 0.007 μM. This compound exhibits notable anti-oxidative stress properties and serves as an inhibitor for the PD-1/PD-L1 pathway. Its biological activities make it valuable for research applications in inflammation, immunity, and cancer studies. -
T-cell Activator
Phytohemagglutinin (PHA-M) is a potent T-cell activator derived from the seeds of Phaseolus vulgaris. This lectin stimulates the proliferation of human mononuclear leukocytes, leading to the upregulation of ChAT mRNA and enhancing acetylcholine synthesis. Additionally, Phytohemagglutinin exerts dose- and time-dependent cytotoxic effects on THP-1 monocytes/macrophages, resulting in altered cellular morphology, organelle dysfunction, and increased expression of pro-inflammatory markers such as NF-κB, COX2, and IL-1β. It is valuable for research applications related to immunology and cell signaling pathways. -
Natural Product
Sesame Oil is a natural product derived from the seeds of Sesamum indicum L. It exhibits a variety of biological activities, including the ability to reduce NF-κB, aspartate aminotransferase, alanine aminotransferase, IL-1β, IL-4, and nitric oxide levels. Sesame Oil demonstrates antitumor activity against malignant melanoma and provides protective effects against liver damage induced by agents such as Cisplatin and Acetaminophen. Additionally, it possesses notable antinociceptive and anti-inflammatory properties, making it a valuable reagent for various research applications. -
NF-KB Activator
Fibrinogen (Bovine) is a glycoprotein that serves as a potent NF-κB activator, exhibiting selective proteolytic properties when activated by thrombin to form fibrin clots. It plays a critical role in regulating NF-κB activation in endothelial cells and enhances the expression of pro-inflammatory chemokines, including MCP-1. Fibrinogen is essential for understanding blood coagulation processes, thrombosis, atherosclerosis, and the pathological aspects of venous graft development, making it valuable for research in vascular diseases. -
CHI3L1 Inhibitor
K284-6111 is a potent inhibitor of CHI3L1, demonstrating high affinity and oral bioavailability. It effectively suppresses CHI3L1 expression and disrupts key signaling pathways, including ERK and NF-κB, leading to reduced nuclear translocation of p50 and p65 as well as decreased phosphorylation of IκB. K284-6111 shows promise in alleviating memory dysfunction associated with Alzheimer's disease by mitigating amyloidogenesis and neuroinflammation. Additionally, it exhibits therapeutic potential in reducing atopic-like skin inflammation and protecting against LPS-induced liver injury. This compound is suitable for research into neurodegenerative diseases and inflammatory conditions. -
Anti-inflammatory Agent
Militarine is an anti-inflammatory agent that primarily targets the NF-κB signaling pathway. It demonstrates significant biological activity by alleviating PM2.5-induced inflammatory injury and inhibiting cell migration in human alveolar epithelial A549 cells. Additionally, Militarine functions as a plant growth inhibitor, affecting the elongation of radicles and hypocotyls in various plant species. This compound is suitable for research applications related to PM2.5-induced pulmonary diseases and plant physiology studies. -
NF-κB Inhibitor
Valencene is a sesquiterpene that functions as an NF-κB inhibitor. It exhibits significant anti-inflammatory, antiallergic, and antioxidant activities by inhibiting the expression of Th2 chemokines and proinflammatory cytokines. In LPS-stimulated RAW 264.7 cells, Valencene effectively reduces the production of IL-1β and IL-6. Additionally, Valencene has demonstrated potential in alleviating symptoms of atopic dermatitis and restoring filaggrin expression in a DNCB-sensitized mouse model. -
Antioxidant
[10]-Shogaol is a potent orally active antioxidant, primarily targeting pro-inflammatory pathways. Derived from ginger (Zingiber officinale), it inhibits cyclooxygenase-2 (COX-2) with an IC50 of 7.5 μM, reducing the production of pro-inflammatory cytokines such as IL-1β and IL-6, and suppressing NF-κB phosphorylation. This compound exhibits notable anti-inflammatory and anticancer activities, particularly against Docetaxel-resistant prostate cancer. Additionally, [10]-Shogaol demonstrates larvicidal efficacy against L5 larvae of Angiostrongylus cantonensis, making it useful for diverse biological research applications. -
Metabolite Of Oroxylin A
Oroxylin A-7-O-glucuronide is a flavonoid glucuronide derivative and metabolite of Oroxylin A, primarily known for its prolyl oligopeptidase inhibitory activity. This compound demonstrates the ability to inhibit the JNK signaling pathway, upregulate PPARγ, and prevent nuclear translocation of NF-κB p65, leading to reduced production of pro-inflammatory cytokines such as IL-1β and IL-6. Additionally, Oroxylin A-7-O-glucuronide exhibits promising anti-angiogenic, anti-tumor, anti-inflammatory, and hepatoprotective properties, making it a valuable tool in cancer research and inflammatory disease studies. -
Flavonoid
Saponarin is a flavonoid compound that functions primarily as an inhibitor of ERK/p38, NF-κB, and MAPK phosphorylation while activating AMPK. It exhibits significant biological activities, including antioxidant, anti-inflammatory, hepatoprotective, hypoglycemic, and hypotensive effects. Additionally, Saponarin has been shown to reduce IL-1β and COX-2 levels, making it relevant for research applications related to inflammation and metabolic disorders. Furthermore, this compound has demonstrated potential in addressing sleep disorders. -
Anti-neuroinflammatory Agent
Murrayafoline A is a carbazole alkaloid that functions as an anti-neuroinflammatory agent by directly targeting Specificity protein 1 (Sp1) and inhibiting the NF-κB and MAPK signaling pathways. This compound induces G0/G1-phase cell cycle arrest in PDGF-stimulated vascular smooth muscle cells and promotes the degradation of β-catenin, thereby attenuating the Wnt/β-catenin pathway. Additionally, Murrayafoline A enhances contractility in rat ventricular myocytes and activates L-type calcium currents through protein kinase C activation. Researchers can utilize Murrayafoline A to investigate inflammation, vascular complications, and colon cancer.
